Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.


Addressing ART Safety and Tolerability in Transgender Individuals

Listen as 2 experts discuss approaches to ART safety and tolerability in transgender individuals, including clinically relevant drug interactions and additional considerations such as gender-affirming care.
Jill Blumenthal, MD, MAS
Jennifer Cocohoba Headshot
Jennifer Cocohoba, PharmD
Released: December 7, 2022

In this episode, Jill Blumenthal, MD, MAS, and Jennifer Cocohoba, PharmD, share how they manage possible antiretroviral (ARV)-associated toxicities in transgender individuals, including:

  • Strategies on how to approach different ARV-related toxicities
  • Other factors to consider when assessing possible ARV-related toxicities (eg, weight gain, cardiovascular disease), such as gender-affirming care and nonmedication risk factors (eg, smoking, life stressors)
  • Clinically relevant drug–drug interactions related to HIV and gender-affirming care
  • Methods to reduce barriers to ART adherence

Information on this Educational Activity


Jill Blumenthal, MD, MAS

Associate Professor of Medicine
Infectious Diseases and Global Public Health
University of California, San Diego
San Diego, California

Jill Blumenthal, MD, MAS: researcher: Gilead Sciences.
Jennifer Cocohoba, PharmD

Department of Clinical Pharmacy
University of California, San Francisco
Women's HIV Program
University of California San Francisco Medical Center
San Francisco, California

Jennifer Cocohoba, PharmD: researcher: Genentech, Janssen, ViiV Healthcare, Walgreens.

Program Medium

This program has been made available online.


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Related Content

Get expert updates on ART safety and tolerability from fall conferences, from Clinical Care Options (CCO)

Eric K. Farmer, PharmD, BCPS, AAHIVP Darcy Wooten, MD Physicians: maximum of 0.5 AMA PRA Category 1 Credits Registered Nurses: 0.5 Nursing contact hours Pharmacists: 0.5 contact hours (0.05 CEUs) Released: January 24, 2023 Expired: January 23, 2024

European pioneers discuss the latest data and guideline recommendations for implementing LA ART into practice, from Clinical Care Options (CCO)

Celia Jonsson-Oldenbuettel, MD, PhD
Program Director
person default Tom Stephane De Wit, MD, PhD Eric Florence, MD, PhD Mireia SantaCreu Guerrero, MSN person default Laurence Slama, MD, PhD
Physicians: maximum of 1.5 AMA PRA Category 1 Credits Released: January 20, 2023 Expired: January 19, 2024

Dr Eric Florence discusses clinic adaptations to promote successful integration of long-acting injectables for HIV in this commentary from Clinical Care Options (CCO)

Eric Florence, MD, PhD Released: January 17, 2023

Listen to expert faculty discuss strategies to promote ART safety and tolerability in aging patients and populations with cardiometabolic toxicities, from Clinical Care Options (CCO)

Marta Boffito, MD, PhD, FRCP Jens D. Lundgren, MD, DMSc Released: January 17, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings